echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > FDA approves oral GnRH-affected antagonist Orgovyx for the treatment of advanced prostate cancer

    FDA approves oral GnRH-affected antagonist Orgovyx for the treatment of advanced prostate cancer

    • Last Update: 2020-12-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Prostate cancer is a malignant tumor that comes from the prostate.
    most prostate cancers grow more slowly, but some still grow relatively quickly.
    cancer cells can be transferred to areas such as bones and lymph nodes.
    may be asymptomatic in the early stages of prostate cancer, which can lead to difficulty urinating, blood urine, back pain, pelvic pain and other symptoms.
    the U.S. Food and Drug Administration (FDA) recently said it has approved Myovant Sciences' GnRH-subject antagonist Orgovyx (relugolix) to treat patients with advanced prostate cancer.
    approval was supported by the HERO trial, which treated more than 900 patients with androgen-sensitive advanced prostate cancer for at least a year for ongoing androgen deprivation.
    patients were randomly treated once a day with Orgovyx or the hormone-targeted drug lysolin.
    results showed that Orgovyx reached the primary therapeutic endpoint, with 96.7 percent of patients receiving treatment achieving continuous testosterone suppression at levels below 50 ng/ dL, while 88.8 percent of patients treated had a deseed level of less than 50 ng / dL.
    , however, the results showed that the drug could not significantly improve the survival rate of patients with desopathic resistance compared to litaquine.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.